Significant licence deal with US biotech
Abzena has recently achieved a significant licensing deal for its proprietary site-specific ThioBridge antibody drug conjugate (ADC) linker technology with a San Diego-based biopharmaceutical company. The agreement covers the use of ThioBridge in up to 10 ADCs across a wide range of indications and a service agreement. This provides important validation of Abzena’s proprietary ADC technology and hybrid business model. Our rNPV valuation increases to £117m following inclusion of the 10 ADCs now being developed through this deal.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.